Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Research Report 2024
The immunoglobulin combination was separated and extracted from normal human plasma by the low-temperature ethanol method, and refined through further processing and virus inactivation steps. This product is a complete, unmodified natural lgG antibody with a purity of up to 98%. It contains no preservatives and antibiotics and is intended for intravenous infusion. Compared with intramuscular gamma globulin, it has a faster effect and a significant effect. advantage.
According to Mr Accuracy reports’s new survey, global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market research.
Key manufacturers engaged in the Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) industry include Boya-Bio, Beijing Tiantan Biological Products, Hualan Bio, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Sinopharm, Shanghai RAAS, CTBB and Nanyue Biopharming, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Boya-Bio
Beijing Tiantan Biological Products
Hualan Bio
Guangdong Shuagnlin Bio-pharmacy
Weiguang Biological
Sinopharm
Shanghai RAAS
CTBB
Nanyue Biopharming
Segment by Type
1g/20ml
1.25g/25ml
2.5g/50ml
5g/100ml
10g/200ml
Hospital
Clinic
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market research.
Key manufacturers engaged in the Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) industry include Boya-Bio, Beijing Tiantan Biological Products, Hualan Bio, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Sinopharm, Shanghai RAAS, CTBB and Nanyue Biopharming, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Boya-Bio
Beijing Tiantan Biological Products
Hualan Bio
Guangdong Shuagnlin Bio-pharmacy
Weiguang Biological
Sinopharm
Shanghai RAAS
CTBB
Nanyue Biopharming
Segment by Type
1g/20ml
1.25g/25ml
2.5g/50ml
5g/100ml
10g/200ml
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices